- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07567937
Effects of Exercise and Short Term Rapid Weight Loss on Whole Blood Cells and Lymphocyte Subsets in Highly Trained National Level Wrestlers (EX-RWL-Lymphoc)
Effects of Exercise and Short-Term Rapid Weight Loss on Whole Blood Cells and Lymphocyte Subsets in Highly Trained National-Level Wrestlers: A Two-Phase Repeated-Measures Study
Wrestling is a weight-classified sport in which athletes frequently apply rapid weight loss (RWL) strategies prior to competition. While the performance-related consequences of RWL have been widely investigated, its combined effects with exercise on hematological parameters and immune cell profiles remain insufficiently understood. Therefore, this study aims to examine the effects of short-term weight loss and exercise on whole blood cell parameters and lymphocyte subsets in elite wrestlers.
Nine elite male wrestlers actively competing in the senior category (mean age: 22.90 ± 5.15 years; mean height: 1.75 m) voluntarily participated in this study. Athletes will achieve an average body mass reduction of 4.3% over a five-day period. Venous blood samples will be collected at 09:30 a.m. in a fasted state during two experimental phases: (1) Exercise-only phase, with blood sampling before and after exercise (BRWL1 and BRWL2); (2) Exercise plus weight loss phase, following the five-day weight loss period, with blood sampling before and after exercise (ARWL1 and ARWL2). Complete blood count parameters will be analyzed using an automated hematology analyzer, while lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, CD16/56+) will be assessed by flow cytometry. Statistical analyses will be performed with a significance level set at p < 0.05.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ankara
-
Ankara, Ankara, Turchia (Türkiye), 06000
- Ankara Yildirim Beyazit University Sports Sciences Laboratory
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Being between 18 and 35 years of age
- Being clinically healthy
- Actively competing in wrestling
- Having regular training experience
- No history of chronic disease
- No musculoskeletal injury that could affect performance
- Not using any medication or nutritional supplements that could influence hematological or biochemical parameters during the study period
- Willing to volunteer and provide written informed consent
Exclusion Criteria:
- Having any chronic disease (e.g., cardiovascular, metabolic, respiratory, or neurological disorders)
- Having a recent musculoskeletal injury that could affect exercise performance
- Using medications, ergogenic aids, or nutritional supplements that might influence hematological or biochemical parameters
- Having a history of smoking or alcohol abuse
- Failing to complete the testing procedures and training protocol required for the study
- Not providing written informed consent
- Withdrawing voluntarily during the study period
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Exercise
Participants performed a standardized wrestling exercise session on the first day of testing.
Venous blood samples were collected pre- and post-exercise (pre-exercise: BRWL1; post-exercise: BRWL2) to evaluate hematological and lymphocyte subset responses.
|
Standardized wrestling exercise session; pre- and post-exercise venous blood collected
Altri nomi:
|
|
Altro: Exercise + Rapid Weight Loss
Participants underwent a 5-day rapid weight loss protocol prior to the exercise session, achieving an average body mass reduction of 4.3%.
On the fifth day, the same standardized exercise protocol as Group 1 was performed, and pre- and post-exercise blood samples were collected (pre-exercise: ARWL1; post-exercise: ARWL2) to evaluate hematological and lymphocyte subset responses.
|
Standardized wrestling exercise session; pre- and post-exercise venous blood collected
Altri nomi:
5-day rapid weight loss protocol achieving average 4.3% body mass reduction
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Leukocyte Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in total white blood cell (WBC) count measured from pre- to post-exercise
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in Lymphocyte Percentage
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in percentage of lymphocytes relative to total WBC count, measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in CD3+ T Cell Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in absolute count of CD3+ T lymphocytes measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in CD4+ T Cell Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in absolute count of CD4+ helper T lymphocytes measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in CD8+ T Cell Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in absolute count of CD8+ cytotoxic T lymphocytes measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in CD19+ B Cell Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in absolute count of CD19+ B lymphocytes measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
|
Change in CD16/56+ NK Cell Count
Lasso di tempo: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Change in absolute count of CD16/56+ natural killer (NK) cells measured from pre- to post-exercise.
|
Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Creatine Kinase and Lactic Acid Levels
Lasso di tempo: Pre-exercise and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Serum creatine kinase (CK) and lactic acid (LA) levels measured to assess anaerobic performance and muscle damage.
|
Pre-exercise and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2280
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .